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ELECTROPHYSIOLOGIC AND ANTIARRHYTHMIC EFFECTS OF 
INTRAVENOUS BISOPROLOL IN ATRIOVENTRICULAR NODAL 
REENTRY TACHYCARDIA 
LOUIS L. M. VAN DE VEN, HARRY J. G. M. CRIJNS, EBO D. DE MUINCK, 
ISABELLE C. VAN GELDER, LEEN M. VAN WIJK, AND KONG I. LIE 
Department of Cardiology, University of Groningen, Groningen, The Netherlands 
ABSTRACT 
Beta-blockade may be useful in the termination and prevention of 
atrioventricular nodal reentry tachycardia (AVNRT). An electrophys- 
iologic study was performed in 9 patients (4 men and 5 women; mean 
f SD age, 56 -+ 16 years) with documented AVNRT before and after 
the intravenous administration of 5 mg of bisoprolol. In 5 of the 9 
patients, AVNRT was terminated by bisoprolol, and AVNRT could no 
longer be induced in 6 of the 9 patients. Bisoprolol significantly pro- 
longed the Wenckebach cycle length but did not affect fast pathway 
refractoriness or atrioventricular (AV) nodal conduction time during 
sinus rhythm or various paced cycle lengths up to 430 milliseconds. 
Conversely, it significantly prolonged the mean atrium-His bundle 
(AH) interval during AVNRT from 244 + 65 milliseconds to 320 + 64 
milliseconds. These observations suggest that the effects of bisoprolol 
on the AV node, primarily at short cycle lengths, are rate dependent. 
Due to AH prolongation, mean tachycardia cycle length significantly 
increased from 313 f 58 milliseconds to 378 -+ 50 milliseconds, but 
there was no difference in the relative amount of prolongation be- 
tween responders (60.8 + 26 ms) and nonresponders (64.6 f 37 ms). 
Bisoprolol appears to be useful in the termination and prevention of 
AVNRT during programmed electrical stimulation studies. Its effects 
on the AV node are use dependent. 
INTRODUCTION 
The induction and maintenance of atrioventricular nodal reentry tachy- 
cardia (AVNRT) are frequently associated with enhanced sympathetic 
tone. 1,2 Beta-blockers may decrease atrioventricular (AV) conduction and 
increase the duration of AV-nodal refractoriness.3 These drugs are effec- 
tive in preventing reinduction of AVNRT by programmed electrical stim- 
ulation (PES) and may suppress clinical attacks.4-6 Bisoprolol is a new, 
highly beta,-selective adrenoreceptor blocking drug without intrinsic sym- 
pathomimetic activity or membrane-stabilizing activity.728 Bisoprolol has 
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not been studied in AVNRT. Because of its pure beta,-adrenoreceptor 
blocking properties, bisoprolol may be especially effective in the adrener- 
gic-dependent forms of supraventricular tachycardias.g*10 
The objective of the present study was to investigate the acute effects 
of bisoprolol on AV-nodal function and initiation and termination of tachy- 
cardia in patients with AVNRT. 
PATIENTSANDMETHODS 
Patients 
Consecutive patients presenting with symptomatic and sustained 
AVNRT, defined as narrow QRS tachycardia lasting at least 30 seconds, 
with a diagnosis confirmed by PES, were enrolled in the study. Only pa- 
tients with symptomatic AVNRT were included; symptoms included diz- 
ziness, palpitations, chest pain, and syncope. Excluded were patients with 
chronic obstructive lung disease and heart failure and patients in whom 
digitalis and other antiarrhythmic agents, including beta-blockers, could 
not be withdrawn. 
The study protocol was approved by the institutional review board of 
Groningen University Hospital, Groningen, The Netherlands. Patients 
were included in the study only after having given their written informed 
consent to participate. 
Study Design 
To evaluate the characteristics of AVNRT at baseline, a 24-hour am- 
bulatory electrocardiographic monitor and upright bicycle exercise test 
were performed. In addition, an arrhythmia questionnaire was completed. 
Bisoprolol was tested during subsequent PES. 
PES was performed in patients in a nonsedated state after they fasted 
overnight. After local lidocaine anesthesia (20 mL of a 1% solution), three 
catheters (U.S.C.I. Bard Electrophysiology, Billerica, Massachusetts) were 
introduced via a femoral vein. One 6-French quadripolar catheter was 
positioned in the high right atrium, and one g-French quadripolar catheter 
was positioned in the right ventricular apex. Lastly, a &French bipolar 
catheter was placed across the tricuspid valve in the His bundle region. 
One additional g-French quadripolar catheter was introduced via the right 
internal jugular vein or the left subclavian vein and positioned in the 
coronary sinus. Blood pressure was continuously monitored through a 
&French arterial catheter in the right femoral artery. Surface electrocar- 
diographic leads I, II, III, and Vi were displayed on a monitor together with 
intracardiac electrograms and recorded on a paperchart recorder or on a 
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computerized system for electrophysiologic signals (EP Lab, Quinton In- 
struments, Milwaukee, Wisconsin). During the electrophysiologic study, 
refractoriness of the atrium, the AV conduction system, and the ventricle 
were determined using the extrastimulus technique during sinus rhythm 
and basic cycle lengths of 600, 500, or 430 milliseconds, with A,S, (the 
interval between the last spontaneous atria1 beat and the extra stimulus) 
or S,S, (the interval between the last driven beat and the extra stimulus), 
decreasing in steps of 10 milliseconds. AVNRT was defined using accepted 
electrophysiologic criteria.” The presence of dual AV-nodal pathways 
was determined using single atria1 extra stimuli and was defined as an 
abrupt prolongation of the atrium-His bundle (AH) interval of at least 50 
milliseconds, after decreasing the extrastimulus interval by 10 millisec- 
onds.12-14 AVNRT was diagnosed only if intra-AV-nodal reentry was 
sustained independent of atria1 or ventricular activation.13 Sinus node 
recovery time and sinoatrial conduction time were determined using the 
method of Strauss et a1.15 
Ten minutes after the induction of AVNRT, 5 mg of bisoprolol was 
given intravenously over a period of 5 minutes, according to a schedule 
used previously.g,10 Forty-five minutes after the end of this bolus injection, 
all electrophysiologic measurements were repeated. If the tachycardia did 
not terminate within 45 minutes after administration of bisoprolol, it was 
terminated by means of overpacing with critically timed atria1 or ventric- 
ular extra stimuli. 
Statistical Analysis 
All data were analyzed descriptively. For continuous variables, the 
mean (*SD), the median, and distribution parameters were calculated. 
Electrophysiologic data from baseline were compared with data obtained 
after bisoprolol infusion. Student’s t test was used for the statistical anal- 
ysis of paired data. 
RESULTS 
Nine patients (4 men and 5 women; age range 44 to 70 years; mean 2 SD 
age, 56 2 16 years) with typical AVNRT were included in the study. All 
patients had documented supraventricular tachycardia on a 12-lead elec- 
trocardiogram. Two patients had daily attacks of tachycardia character- 
ized by episodes of palpitations lasting at least 1 minute, accompanied by 
chest pain. Four patients experienced weekly episodes of palpitations; in 
two of these patients, the palpitations were accompanied by chest pain, and 
in three of these patients, the palpitations were accompanied by presyn- 
cope. Three patients had monthly episodes of palpitations; in two of these 
patients, the palpitations were occasionally accompanied by syncope, 
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whereas the other patient complained of chest pain and dizziness during 
these attacks. 
All patients had been treated unsuccessfully with antiarrhythmic 
drugs (2 patients had received propranolol, 1 had received sotalol, 1 had 
received flecainide, 4 had received verapamil, and 1 had received disopyr- 
amide combined with verapamil). There were no episodes of tachycardia 
during bicycle exercise testing.16 During Holter monitoring, all patients 
had symptomatic episodes of narrow complex tachycardia. In total, 14 
symptomatic episodes of nonsustained supraventricular tachycardias were 
registered. 
The electrophysiologic variables before and after administration of 
bisoprolol are summarized in the table. Apart from a significant prolon- 
gation of the sinus cycle length, the AH interval, and the Wenckebach 
point (P < 0.051, there were no significant changes in electrocardiographic 
and intracardiac conduction intervals and refractory periods during sinus 
rhythm or paced cycle lengths. In seven of the nine patients, dual AV- 
nodal physiology was demonstrated at baseline. 
After the initiation of AVNRT, bisoprolol terminated the arrhythmias 
in five patients. In the other patients, tachycardia was terminated 45 
minutes after the start of bisoprolol, with one critically timed extra stim- 
ulus in the right ventricular apex in one patient and 2 or 3 critically timed 
extra stimuli in the right atrium in the three other patients. 
Table. Electrocardiographic (ECG) and electrophysiologic variables before and after admin- 
istration of bisoprolol. Values are given as mean + SD. 
Sinus cycle length* 
AH interval 
HV interval 







Refractory period HRA 
Refractory period RVA 




‘7; : 1:” 
44 I 6 
116 k 48 
945 + 89 
978 + 102 
867 2 199 
“Z : Z” 
“+ + 272 351 41 36
245 + 29 
255 2 18 
;:; r :: + 
Bisoprolol (ms) 
145 k 59 
1038 ? 154t 
1046 t 15lt 
1080 5 176t 
9i; f ;:3t 
338 : 57T 
;;; : ;: 
247 : 17 
z: : ::I + 
ms = milliseconds; AH = atrium-His bundle; HV = His bundle-ventricle; SNRT = sinus node recovery 
time; QRS = electrocardiographic (ECG) wave segment; HRA = high right atrium; RVA = right ventricular 
?pex. 
Atrial and ventricular refractory periods were determined at basic cycle length of 500 milliseconds. 
t P < 0.05. 
$ SNRT determined after atrial burst pacing at cycle lengths of 550, 500, 450, and 400 milliseconds. 
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Mean tachycardia cycle length (TCL) increased from 313 + 58 milli- 
seconds to 378 + 50 milliseconds (P < 0.05) 10 minutes after the start of 
bisoprolol and was 380 + 33 milliseconds 30 minutes later (P < 0.05). 
Patients in whom tachycardia was terminated with bisoprolol had a sim- 
ilar increase in TCL (60.8 5 26 milliseconds) compared with the other 
patients (64.6 ? 37 milliseconds). The change in cycle length was due to a 
significant increase in the AH interval from 244 ? 65 milliseconds to 320 
+ 64 milliseconds, 5 minutes after the start of the infusion (P s 0.05). 
Forty-five minutes after the end of the infusion, AVNRT could not be 
reinduced in six patients. Tachycardia was no longer inducible in four of 
the five patients in whom tachycardia was terminated with bisoprolol. 
Also, in two other patients, in whom the arrhythmias were terminated 
with extra stimuli, AVNRT was no longer inducible. The relationship 
between TCL and the AH and His bundle-atrium intervals during tachy- 
cardia is shown in Figure 1. 
In all patients, there was a marked drop in blood pressure after initi- 
ation of AVNRT. The relationship between TCL and mean systolic blood 
pressure is shown in Figure 2. 





0 AH interval 
_ + HA interval 
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Time after Bisoprolol (min) 
Figure 1. The relationship between tachycardia cycle lengths (TCL), atrium-His bundle 
(AH) intervals, and His bundle-atrium (HA) intervals. Values are given as mean 
Z!I SE. Note that the increase in TCL is due mainly to the increase in the AH 
intervals. ms = milliseconds. 
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Figure 2. Systolic blood pressure @BP) and tachycardia cycle length (TCL) in all patients at 
baseline (during sinus rhythm), immediately after the onset of atrioventricular 
nodal reentry tachycardia (AVNRT), and 1, 10, and 45 minutes after the start of 
bisoprolol and at the end of programmed electrical stimulation. Values are given as 
mean 2 SD. ms = milliseconds. 
119 2 26 mm Hg. This initial drop in blood pressure was not aggravated 
by the administration of bisoprolol. Ten minutes after drug administra- 
tion, mean systolic blood pressure was 118 2 16 mm Hg. The increase in 
TCL due to bisoprolol was paralleled by an increase in blood pressure. 
Adverse events observed by the investigator or study nurse or reported 
by the patient were to be documented on the case record form. However, no 
adverse events were reported. 
DISCUSSION AND CONCLUSIONS 
In five of nine patients with induced, sustained AVNRT, tachyarrhyth- 
mias were terminated within 45 minutes after the intravenous adminis- 
tration of bisoprolol. After bisoprolol, tachycardia was no longer inducible 
in six patients. In all patients, termination of the arrhythmias was asso- 
ciated with a significant slowing of the tachycardia due to the slowing of 
the anterograde slow pathway conduction as evidenced by an increase in 
the AH interval during AVNRT. Obviously, these results should be inter- 
preted with caution because this was an uncontrolled, open-label study. 
AVNRT is often encountered in patients without any further evidence 
of cardiovascular disease. This may hold true especially for young pa- 
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tients.i7 AV-nodal tachycardia is mostly due to reentry within the AV 
node, based on critical differences in conduction time. Presumably, the 
differences in conduction times are preexistent but may become enhanced 
by fibrosis or myxedema infiltration of the AV node such as occurs in 
patients with hypothyroidism. In one of the patients in this study, hypo- 
thyroidism may have contributed to AVNRT. In the older patients in this 
study, fibrosis may have played a role in the development of AVNRT. The 
oldest patient in this study, a 70-year-old woman, is noteworthy because 
she only had a brief history of complaints of palpitations and syncope. 
Apart from these considerations, the effects of catecholamines on the AV 
node appear to have been an important pathogenic factor in this patient 
group, which is consistent with the relatively high efficacy of beta- 
blockage with bisoproloL2 
Adrenergic blockade slows conduction and prolongs refractoriness in 
both the anterograde and retrograde directions. With regard to the effects 
of bisoprolol on electrocardiographic and intracardiac conduction times as 
well as on refractory periods, the data are in agreement with that found 
with other beta-blockers.” The same holds true for the termination of 
induced AVNRT. In the current study, a high percentage of AVNRT ter- 
mination (56%) and prevention of reinitiation of AVNRT (67%) was found. 
Although the use of bisoprolol has been investigated previously in three 
electrophysiologic studies,g,‘O~lg these investigations did not study 
AVNRT. The fact that bisoprolol exerts its influence mainly on the AV 
node is in keeping with its selective beta-adrenergic antagonism. It is well 
known that intravenous beta-adrenergic blockers given to patients at rest 
have little or no effect on accessory pathway refractoriness and conduc- 
tion.20s21 The slowing and termination of AVNRT are, however, mainly 
due to the effect of bisoprolol on slow pathway conduction. In addition, 
bisoprolol may suppress premature atria1 beats, which may initiate 
AVNRT. Therefore, intravenous beta-blockade may be effective in termi- 
nating AVNRT, especially in patients in whom initiation and sustaining of 
the arrhythmia is dependent on an increased sympathetic drive. 
Results from the Cardiac Arrhythmia Suppression Trial and prelim- 
inary results from the Survival with Oral D-Sotalol trial have indicated 
that class Ic and class III drugs may provoke ventricular proarrhyth- 
mias.22 Beta-blockade does not provoke this type of proarrhythmia.” On 
the other hand, beta-blockade may aggravate sick sinus syndrome or com- 
promise AV-nodal conduction. However, the latter is unlikely in a rela- 
tively young patient population suffering from AVNRT. AVNRT may also 
be treated with radiofrequency ablation techniques, but the latter are still 
associated with a significant rate of recurrence of arrhythmias and risk of 
AV block, necessitating pacemaker implantation.23 
A relatively low dose (5 mg) of bisoprolol given intravenously was 
chosen to avoid aggravation of the hypotension that can be expected after 
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induction of tachyarrhythmia. 3~11 No detrimental effects on hemodynamic 
performance were found. The rise in blood pressure during the induced 
tachycardia seen in all patients after intravenous administration of biso- 
pro101 was accompanied by a significant slowing of the tachycardia. There- 
fore, rate appears to be the most important determinant of blood pressure 
reduction during AVNRT, and blood pressure is not negatively affected by 
bisoprolol. This suggests that the increased duration of diastole (with the 
atria1 contribution to filling still absent) played an important part in the 
increase in blood pressure. Apart from its high beta,-selectivity, the fact 
that bisoprolol did not aggravate the hypotension caused by AVNRT is a 
favorable property of this drug and warrants further investigation with a 
higher dose and/or comparison with other beta-blockers, especially in pa- 
tients with adrenergic-drive-dependent AVNRT.* Further research into 
the efficacy of oral beta-blocker treatment for the prevention of AVNRT 
appears indicated, especially in view of the adverse effects of class Ic and 
class III agents and the risks of radiofrequency ablation.23 
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